Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 1;15(1):20.
doi: 10.1186/s13037-021-00291-9.

Review the safety of Covid-19 mRNA vaccines: a review

Pratibha Anand  1 , Vincent P Stahel  2
Affiliations
Review

Review the safety of Covid-19 mRNA vaccines: a review

Pratibha Anand et al. Patient Saf Surg. .

Erratum in

Abstract

The novel coronavirus disease 2019 (COVID-19) has infected more than 100 million people globally within the first year of the pandemic. With a death toll surpassing 500,000 in the United States alone, containing the pandemic is predicated on achieving herd immunity on a global scale. This implies that at least 70-80 % of the population must achieve active immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), either as a result of a previous COVID-19 infection or by vaccination against SARS-CoV-2. In December 2020, the first two vaccines were approved by the FDA through emergency use authorization in the United States. These vaccines are based on the mRNA vaccine platform and were developed by Pfizer/BioNTech and Moderna. Published safety and efficacy trials reported high efficacy rates of 94-95 % after two interval doses, in conjunction with limited side effects and a low rate of adverse reactions. The rapid pace of vaccine development and the uncertainty of potential long-term adverse effects raised some level of hesitation against mRNA vaccines in the global community. A successful vaccination campaign is contingent on widespread access to the vaccine under appropriate storage conditions, deployment of a sufficient number of vaccinators, and the willingness of the population to be vaccinated. Thus, it is important to clarify the objective data related to vaccine safety, including known side effects and potential adverse reactions. The present review was designed to provide an update on the current state of science related to the safety and efficacy of SARS-CoV-2 mRNA vaccines.

Keywords: COVID-19; Coronavirus; SARS-CoV-2; Vaccine safety; mRNA vaccine.

PubMed Disclaimer

Conflict of interest statement

There are no financial conflicts of interest related to this editorial.

The authors declare that the content of this review article represents their exclusive personal opinion, and does not reflect the official position of any health care entity, including hospitals and associated facilities, health care systems, or professional societies and agencies.

Figures

Fig. 1
Fig. 1
Structure of the SARS-CoV-2 virus. (M) Membrane protein. (N) Nucleocapsid (capsid protein & RNA). (S) Spike protein. (L) Lipid bilayer
Fig. 2
Fig. 2
COVID-19 mRNA vaccination mechanism. The mRNA vaccine is injected by intramuscular route, typically into the deltoid muscle. The lipid coat vehicle around the mRNA allows for the vaccine to enter the cytosol of the cell. The ribosomes translate the mRNA into spike proteins. The injected mRNA subsequently degrades. The spike proteins are released from the cell and initiate an adaptive immune response. Through various activation pathways, immune cells mount a cell-mediated and antibody-mediated immunity against the spike protein of the SARS-CoV-2 virus
See this image and copyright information in PMC

References

    1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID–19): a review. JAMA. 2020;324(8):782–793. - PubMed
    1. Vabret N. Preclinical data from SARS-CoV–2 mRNA vaccine. Nat Rev Immunol. 2020;20(8):461. - PMC - PubMed
    1. Ahammad I, Lira SS. Designing a novel mRNA vaccine against SARS-CoV–2: An immunoinformatics approach. Int J Biol Macromol. 2020;162:820–837. - PMC - PubMed
    1. Rahman IU, Ali N, Ijaz F, Afzal A, Abd Allah EF. COVID–19 - Important considerations for developing and using a vaccine. Hum Vaccin Immunother. 2020:1–2. - PMC - PubMed
    1. Lombard M, Pastoret PP, Moulin AM. A brief history of vaccines and vaccination. Rev Sci Tech. 2007;26(1):29–48. - PubMed